Abstract:Background: The EQ-5D-5L is a generic preference-based questionnaire developed by the EuroQol Group to measure health-related quality of life (HRQoL) in 2005. Since its development, it has been increasingly applied in populations with various diseases and has been found to have good reliability and sensitivity. This study aimed to summarize the health utility elicited from EQ-5D-5L for patients with different diseases in cross-sectional studies worldwide. Methods: Web of Science, MEDLINE, EMBASE, and the Cochrane Library were searched from January 1, 2012, to October 31, 2019. Cross-sectional studies reporting utility values measured with the EQ-5D-5L in patients with any specific disease were eligible. The language was limited to English. Reference lists of the retrieved studies were manually searched to identify more studies that met the inclusion criteria. Methodological quality was assessed with the Agency for Health Research and Quality (AHRQ) checklist. In addition, meta-analyses were performed for utility values of any specific disease reported in three or more studies. Results: In total, 9,400 records were identified, and 98 studies met the inclusion criteria. In the included studies, 50 different diseases and 98,085 patients were analyzed. Thirty-five studies involving seven different diseases were included in meta-analyses. The health utility ranged from 0.31 to 0.99 for diabetes mellitus [meta-analysis random-effect model (REM): 0.83, (95% CI = 0.77–0.90); fixed-effect model (FEM): 0.93 (95% CI = 0.93–0.93)]; from 0.62 to 0.90 for neoplasms [REM: 0.75 (95% CI = 0.68–0.82); FEM: 0.80 (95% CI = 0.78–0.81)]; from 0.56 to 0.85 for cardiovascular disease [REM: 0.77 (95% CI = 0.75–0.79); FEM: 0.76 (95% CI = 0.75–0.76)]; from 0.31 to 0.78 for multiple sclerosis [REM: 0.56 (95% CI = 0.47–0.66); FEM: 0.67 (95% CI = 0.66–0.68)]; from 0.68 to 0.79 for chronic obstructive pulmonary disease [REM: 0.75 (95% CI = 0.71–0.80); FEM: 0.76 (95% CI = 0.75–0.77)] from 0.65 to 0.90 for HIV infection [REM: 0.84 (95% CI = 0.80–0.88); FEM: 0.81 (95% CI = 0.80–0.82)]; from 0.37 to 0.89 for chronic kidney disease [REM: 0.70 (95% CI = 0.48–0.92; FEM: 0.76 (95% CI = 0.74–0.78)]. Conclusions: EQ-5D-5L is one of the most widely used preference-based measures of HRQoL in patients with different diseases worldwide. The variation of utility values for the same disease was influenced by the characteristics of patients, the living environment, and the EQ-5D-5L value set. Systematic Review Registration : https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD42020158694.

Healthcare consumer acceptability of routine use of the EQ-5D-5L in clinical care: a cross-sectional survey

Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective

Health-Related Quality of Life in Patients with Different Diseases Measured with the EQ-5D-5L: A Systematic Review

Implementing routine collection of EQ-5D-5L in a breast cancer outpatient clinic

Validation of the EQ-5D in a general population sample in urban China

Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set

Measurement Properties of the EQ-5D-5L in Sub-Health: Evidence Based on Primary Health Care Workers in China

EQ-SD: a measure of health status from the EuroQol Group

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

Is EQ-5D-Y a useful tool to assess health outcomes in children with asthma? An analysis of child and caregiver reporting.

Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey

Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescents with cystic fibrosis

Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds

The use of the EQ-5D as a measure of health-related quality of life in people with dementia and their carers

Exploring health preference heterogeneity in the UK: Using the online elicitation of personal utility functions approach to construct EQ‐5D‐5L value functions on societal, group and individual level

Validation and Comparison of the Sf-6d and Eq-5d in Chinese Patients with Moderate to Severe Psoriasis

Health-related quality of life in primary care patients: a comparison between EQ-5D-5L utility score and EQ-visual analogue scale

A head-to-head comparison of EQ health and wellbeing (EQ-HWB) and EQ-5D-5L in patients, carers, and general public in China

How do children understand and respond to the EQ-5D-Y-3L? A mixed methods study in a community-based sample of 6–12-year-olds

Collection and use of EQ-5D for follow-up, decision-making, and quality improvement in health care - the case of the Swedish National Quality Registries

Testing the psychometric characteristics of EQ-5D-5L and respiratory bolt-ons using a sample of the Australian population